16 February 2020
COSMED Acquires Innovision ApS Technology
COSMED Announces Acquisition of Innovision Technology to Expand Product Portfolio and Presence in the Nordic Markets.
COSMED headquartered in Rome, Italy, leading manufacturer of Metabolic and Body composition technologies, has acquired assets of Innovision ApS, a Danish Company with significant know-how and expertise in the design of products for Hemodynamic (Cardiac Output), Ventilation Heterogeneity (Lung Clearance Index) and Metabolic measurements (VO2Max).
Innovision’s products are a perfect match to COSMED’s product portfolio in Pulmonary Function Testing and Metabolic measurements with virtually no overlap. The newly incorporated COSMED Nordic ApS with headquarters in Glamsbjerg, Denmark, is the new manufacturer of Innovision products that will be distributed worldwide through COSMED Direct and Distributors channels.
Innovision, is a specialized developer and manufacturer of devices for non-invasive measurements of Cardiac output and Ventilation heterogeneity. The company’s core expertise is use of inert tracer gases combined with advanced technologies for gas analysis and mathematical gas exchange models. To know more visit www.innovision.dk
COSMED, established in 1980, is a privately-owned company that designs and manufactures cardio pulmonary and metabolic diagnostic equipment. COSMED solutions address needs of the healthcare, academic and industry markets to assess human metabolism, exercise physiology, pulmonary function and body composition for clinical and research purposes. COSMED products include a full range of spirometers, indirect calorimetry, cardio pulmonary exercise testing and body composition systems including software. COSMED headquarters are located in Rome, Italy with direct operations in Australia, France, Germany, Hong Kong, Netherlands, Switzerland, UK and United States, and a network of business partners covering more than 80 countries.
Jørgen G. Nielsen, MD, PhD